To study the effect of endostar on the expression of hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF) and radiosensitization, the changes of A549 cells treated by endostar, radiotherapy and radiotherapy plus endostar were checked by flow cytometry (FCM), methyl thiazolyl tetrazolium (MTT), hoechst staining, and enzyme linked immunosorbent assay (ELISA). The results showed that endostar could block cell periods of A549 and stopped the cell cycle at G2/M and S periods. Cell growth inhibiting and apoptotic rate in the combination group were higher than those in other groups. Meanwhile, the levels of HIF-1 and VEGF expression in the combination group were lower than those of other groups. It suggested that endostar significantly sensitizes the function of radiation in A549 cells by arresting the cell cycle at stage of G2/M and S, increasing the cell growth inhibiting and the apoptotic rate, down-regulating the expression of HIF-1 and VEGF.

No abstract

This paper analysis the patients with early non-small cell lung cancer treated by thoracoscopy. Methods: 96 patients with non-small cell lung cancer treated in our hospital from 2004 to 2016 were divided into control group and study group according to the random assignment method. The thoracic surgery was performed in the control group and the thoracic surgery was performed in the control group. The therapeutic effect of the two groups was compared. Results: Compared with the two groups, there was no significant difference in the number of lymph node dissection between the two groups (P> 0.05). There was no significant difference between the two groups in the amount of bleeding, drainage time and postoperative pain time is better than thoracotomy surgery group, the two groups were different P <0.05 and it has statistically significant. Conclusion: Thoracoscopic surgery for early non-small cell lung cancer (NSCLC) is effective for lymph node dissection, and it has the characteristics of less trauma, less complication, less hospital stay and less healing time. It is worthy of clinical application.

In order to investigate the efficacy of combining radiation therapy with endostar on Lewis lung carcinoma in mice and the interaction mechanisms of combined therapy. Tumor models were established in the hind limb of female C57 BL/6N mice by subcutaneous transplantation. The tumorbearing mice were randomly divided into 4 groups: control group, endostar group (20 mg·kg -1 , once daily for 15 days), radiotherapy group (2 Gray per day to 10 Gray, d6-d10), and radiotherapy plus endostar group (combination group), (n=10 in each group). The tumors were applied to analysis of the tumor inhibitory rate and growth curve. Immunohistochemisty was adopted to check the expressions of microvessel density (MVD). The expression levels of Hypoxia-inducible factor 1α (HIF-1α) mRNA was tested by real-time fluorescence quantitative polymerase chain reaction (RT-PCR). The results demonstrated that the tumor inhibitory rate in combined treatment group was higher than that in other groups. Meanwhile, MVD and the level of HIF-1α mRNA were lower than that in other groups. We concluded that endostar significantly sensitized the function of radiation on Lewis lung carcinoma in mice, and this effect is working by decreasing HIF-1α, thereby increasing the killing effect of radiation on tumor cells.

Background: Anlotinib is one of the tyrosine kinase inhibitors that exhibits promising anti-tumor effect in several cancers. However, the efficacy and safety of anlotinib in pre-treated small cell lung cancer (SCLC) is not well determined. Herein, we performed this meta-analysis to summarize the effectiveness and safety of anlotinib in the treatment of pre-treated SCLC. Methods: The databases, such as PubMed and Embase, were searched to identify eligible studies. Clinical studies reporting the efficacy and safety of anlotinib in the treatment of patients with pre-treated SCLC were included. The main endpoints were overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and adverse events. The Review Manager 5.4 and STATA 14 statistical software were used to perform the meta-analysis. Results: A total of 13 studies were included, involving 779 patients with SCLC. The ORR and DCR for the anlotinib group were 0.21 (95%CI: 0.12- 0.31; p < 0.01) and 0.76 (95%CI: 0.69- 0.83; p < 0.01), respectively. The summarized PFS and OS for the anlotinib group were 3.46 (95%CI: 2.68-4.24), and 6.86 (95%CI: 5.79-7.93) months, respectively. Compared with control group, the PFS in the anlotinib group was significantly longer standard mean difference(SMD)=0.76, 95%CI: 0.11, 1.41; p = 0.02). In terms of safety, the most common grade 3 or higher adverse events in the anlotinib group were hypertension (9%; 95%CI: 6%-13%), hand-foot syndrome (6%; 95%CI: 2%-9%), and fatigue (4%; 95%CI: 2%-7%). Conclusions: Anlotinib may be associated with favorable efficacy outcomes in pre-treated SCLC patients with acceptable safety.